Sidley advised Akeso Inc. on the deal. Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Yisheng Biopharma Co., Ltd. on the deal, while Sidley Austin LLP and Maples and Calder advised R-Bridge Healthcare Fund. Yisheng Biopharma Co.,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Tyra Biosciences in the offering while Sidley advised the underwriters. Tyra Biosciences, Inc. has announced the pricing of its upsized initial public offering of...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Interius BioTherapeutics on the deal. Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Tempest Therapeutics, Inc. on the deal. Tempest Therapeutics, Inc., a privately-held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted...
You must be a Standard 1 Year member to access this content.
